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AnBACKGROUND Renal denervation (RDN) is under investigation for treatment of uncontrolled hypertension and might
represent an attractive treatment for patients with high cardiovascular (CV) risk. It is important to determine whether
baseline CV risk affects the efficacy of RDN.
OBJECTIVES The purpose of this study was to assess blood pressure (BP) reduction and event rates after RDN in patients
with various comorbidities, testing the hypothesis that RDN is effective and durable in these high-risk populations.
METHODS BP reduction and adverse events over 3 years were evaluated for several high-risk subgroups in the GSR
(Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry), an
international registry of RDN in patients with uncontrolled hypertension (n ¼ 2,652). Comparisons were made for pa-
tients age $65 years versus age <65 years, with versus without isolated systolic hypertension, with versus without atrial
fibrillation, and with versus without diabetes mellitus. Baseline cardiovascular risk was estimated using the American
Heart Association (AHA)/American College of Cardiology (ACC) atherosclerosis cardiovascular disease (ASCVD) risk score.
RESULTS Reduction in 24-h systolic BP at 3 years was 8.9  20.1 mm Hg for the overall cohort, and for high-risk
subgroups, BP reduction was 10.4  21.0 mm Hg for resistant hypertension, 8.7  17.4 mm Hg in patients age $65
years, 10.2  17.9 mm Hg in patients with diabetes, 8.6  18.7 mm Hg in isolated systolic hypertension, 10.1 
20.3 mm Hg in chronic kidney disease, and 10.0  19.1 mm Hg in atrial fibrillation (p < 0.0001 compared with baseline
for all). BP reduction in patients with measurements at 6, 12, 24, and 36 months showed similar reductions in office and
24-h BP for patients with varying baseline ASCVD risk scores, which was sustained to 3 years. Adverse event rates at
3 years were higher for patients with higher baseline CV risk.
CONCLUSIONS BP reduction after RDNwas similar for patients with varying high-risk comorbidities and across the range
of ASCVD risk scores. The impact of baseline risk on clinical event reduction by RDN-induced BP changes could be eval-
uated in further studies. (Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3
Years Registry; NCT01534299) (J Am Coll Cardiol 2020;75:2879–88) © 2020 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2020.04.036
m the aDepartment of Internal Medicine, Saarland University Hospital, Homburg/Saar, Germany; bUniversity of Milano-Bicocca
d Policlinico di Monza, Monza, Italy; cDepartment of Nephrology and Hypertension, University Hospital Erlangen, Erlangen,
rmany; dDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland; eDepartment of Car-
vascular Risk, Hospital Universitario 12 de Octubre and CIBERCV and School of Doctoral Studies and Research, Universidad
ropea de Madrid, Madrid, Spain; fDepartment of Medicine, Dobney Hypertension Centre, School of Medicine–Royal Perth
spital Unit, The University of Western Australia, Perth, Western Australia, Australia; gDepartment of Cardiology, Saint Vincent’s
spital, Melbourne, Victoria, Australia; hDepartment of Cardiology, Medizinische Universität Graz, Graz, Austria; iDepartment of
giology, Universitäts-Herzzentrum Freiburg, Bad Krozingen, Germany; jDepartment of Cardiology, Deutsches Herzzentrum
ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial fibrillation
ASCVD = atherosclerotic
cardiovascular disease
BP = blood pressure
CV = cardiovascular
DM = diabetes mellitus
ISH = isolated systolic
hypertension
RDN = renal denervation
SBP = systolic blood pressure
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2880T hree recent sham-controlled trialsverified the short-term (2 to6 months) safety and efficacy of
renal denervation (RDN) in patients with un-
controlled hypertension and relatively few
comorbidities (1–3). However, whether pa-
tients with comorbidities associated with
increased sympathetic activity or with over-
all higher cardiovascular risk have a differing
blood pressure (BP)–lowering response
following RDN is unknown. It is also uncer-
tain whether the durability of the BP-
lowering effect of RDN could be limited dueto disease progression or differences in response in
these subpopulations (4). Finally, the rates of clinical
events as well as longer-term safety of RDN are not
well described.SEE PAGE 2889The GSR (Global proSpective registrY for syMPa-
thetic renaL denervatIon in seleCted IndicatIons
Through 3 Years Registry) is an ongoing, multi-
center, international single-arm trial with planned
enrollment of 3,000 patients with varying cardio-
vascular (CV) risk who are followed up to 3 years
after RDN. We evaluated short- and long-term BP
reduction, clinical events, and adverse event rates
after RDN in patients with various comorbidities
and baseline CV risk to test the hypothesis of
whether RDN is effective and durable in these high-
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TRIAL DESIGN. The design of the GSR (NCT01534299)
has been previously published (5). In this interna-
tional, prospective, single-arm registry, patients are
enrolled with uncontrolled hypertension and/or
conditions associated with sympathetic nervous sys-
tem activation. Uncontrolled hypertension was
defined as BP above recommended levels (regardless
of therapy) according to published local guidelines at
the time of enrollment. Sympathetic nervous system
activation was defined as conditions associated with
increased sympathetic nervous system activity,
including diabetes, congestive heart failure, chronic
kidney disease, obstructive sleep apnea, or arrhyth-
mias. The study was approved by the institutional
review board or ethics committee at each enrolling
site, and the trial adhered to the Declaration
of Helsinki.
All patients are treated with the Symplicity RDN
system (Medtronic, Santa Rosa, California) using
either the Symplicity Flex or Symplicity Spyral cath-
eter. The primary objective of the study was to
document long-term safety and effectiveness of RDN
in a real-world patient population. Follow-up is rec-
ommended for 3 years post-RDN. Key endpoints
measured in this prospective registry include BP
measurements and changes in medications. All
protocol-defined safety events were adjudicated by
an independent clinical events committee (Cardio-
vascular Research Foundation, New York, New York).PLC, Santa Rosa, California; and the lDepartment of
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TABLE 1 Changes in 24-h and Office SBP at 6, 12, 24, and 36 Months Post-Procedure Compared With Baseline for All Patients
Baseline
Change From Baseline at
6 Months 12 Months 24 Months 36 Months
24-h SBP, mm Hg 154.5  18.2
(n ¼ 1,844)
7.5  17.9 (8.5 to 6.4)
(n ¼ 1,133)
8.4  18.6 (9.6 to 7.3)
(n ¼ 1,020)
9.0  19.6 (10.4 to 7.5]
(n ¼ 690)
8.9  20.1 (10.7 to 7.1]
(n ¼ 500)
Office SBP, mm Hg 166.1  24.8
(n ¼ 2,576)
13.1  26.2 (14.3 to 12.0)
(n ¼ 1,986)
14.1  26.7 (15.3 to 12.9)
(n ¼ 1,887)
15.4  27.5 (16.8 to 14.0]
(n ¼ 1,459)
16.5  28.5 (18.1 to 14.9]
(n ¼ 1,183)
Values are mean  SD (95% confidence interval).
SBP ¼ systolic blood pressure.
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quality of the data.
DEFINITIONS. Post hoc analyses were completed for
various high-risk subgroups, including: elderly pa-
tients (age $65 years) and patients with atrial
fibrillation (AF), diabetes mellitus (DM) type II, se-
vere treatment resistant hypertension (office sys-
tolic blood pressure [SBP] >150 mm Hg despite
prescription of $3 antihypertensive medications),
chronic kidney disease (estimated glomerular
filtration rate <60 ml/min/1.73 m2), and isolated
systolic hypertension (ISH) (baseline office
SBP $140 mm Hg and diastolic BP <90 mm Hg).
Baseline atherosclerotic cardiovascular disease
(ASCVD) risk scores were calculated for patients
with available office SBP measurements, antihyper-
tensive medications, and cholesterol measurements,
as well as diabetic and smoking status (6). Efficacy
was assessed by serial office and, where available,
ambulatory BP measurements over the 3 years of
follow-up following RDN.TABLE 2 24-h and Office SBP Reduction for Patients With BP Measur
ASCVD Risk Score and Adjusted Using ANCOVA
AS
<10%
(n ¼ 290)
$
24-h SBP, mm Hg n ¼ 66 matched patients n ¼ 58
Baseline 152.3  18.1 1
Change at 6 months 8.4  22.2 (13.8 to 2.9) 6.8 
Change at 12 months 9.4  21.2 (14.6 to 4.1) 6.4 
Change at 24 months 7.8  22.6 (13.4 to 2.3) 6.8 
Change at 36 months 8.6  24.1 (14.5 to 2.6) 6.0 
Office SBP, mm Hg n ¼ 152 matched patients n ¼ 116
Baseline 156.6  21.5 1
Change at 6 months 9.5  25.4 (13.6 to 5.5) 8.4 
Change at 12 months 10.4  24.7 (14.4 to 6.5) 11.6 
Change at 24 months 10.2  24.3 (14.1 to 6.3) 11.7  2
Change at 36 months 6.3  27.1 (10.7 to 2.0) 15.7  2
Values are mean  SD (95% confidence interval). *Statistical significance defined as p <
ASCVD ¼ atherosclerotic cardiovascular disease; SBP ¼ systolic blood pressure.STATISTICAL ANALYSIS. Continuous variables were
presented as mean  SD. Between-group differences
in continuous variables were tested using analysis
of covariance (ANCOVA), adjusting for baseline BP.
Within-group differences in continuous variables
from baseline to follow-up were tested using paired
t-tests. To account for multiple comparisons over
time points, the significance level was determined
by the Bonferroni method as indicated in the table
and figure footnotes. Categorical variables were
presented as counts and percentages and were
compared between groups using the Fisher exact
test for binary variables and chi-square test for
multilevel categorical variables. Some BP measure-
ments at follow-up were adjusted for baseline BP
using ANCOVA analyses. These measurements were
not adjusted for differences in other baseline
covariates. Analyses were performed according to
the intention-to-treat principle. BP reduction and
adverse events were compared for patients with
baseline ASCVD risk scores <10%, $10% and <20%,ements at Baseline, 6, 12, 24, and 36 Months, Stratified by Baseline
CVD Risk Score
10% to <20%
(n ¼ 239)
$20%
(n ¼ 510) p Value*
matched patients n ¼ 125 matched patients
48.6  16.7 149.1  14.9 0.39
16.7 (11.1 to 2.4) 7.1  13.7 (9.5 to 4.7) 0.93
18.3 (11.2 to 1.6) 7.3  16.1 (10.1 to 4.4) 0.97
19.8 (12.0 to 1.6) 10.5  15.5 (13.3 to 7.8) 0.08
19.2 (11.0 to 0.9) 7.6  16.2 (10.5 to 4.8) 0.72
matched patients n ¼ 236 matched patients
58.4  24.5 166.0  22.7 <0.001
25.7 (13.1 to 3.7) 15.9  24.8 (19.1 to 12.8) 0.91
24.5 (16.1 to 7.1) 15.9  28.1 (19.5 to 12.3) 0.60
5.9 (16.4 to 6.9) 16.1  27.4 (19.6 to 12.5) 0.74
5.5 (20.4 to 11.0) 17.1  27.1 (20.6 to 13.6) 0.06
0.0125 by Bonferroni adjustment.
TABLE 3 Changes in 24-h and Office SBP at 6, 12, 24, and 36 Months Post-Procedure From Baseline for Patients in High-Risk Subgroups
Baseline
Change From Baseline at
6 Months 12 Months 24 Months 36 Months
24-h SBP, mm Hg
Resistant
hypertension
157.5  18.2
(n ¼ 1,274)
8.1  17.9 (9.3 to 6.8)
(n ¼ 751)
9.5  18.9 (10.9 to 8.1)
(n ¼ 670)
10.2  20.1 (12.1 to 8.3)
(n ¼ 441)
10.4  21.0 (12.7 to 8.0)
(n ¼ 302)
Age $65 yrs 152.4  17.5
(n ¼ 758)
6.1  16.1 (7.6 to 4.6)
(n ¼ 460)
6.9  16.6 (8.5 to 5.3)
(n ¼ 417)
7.8  18.0 (10.0 to 5.7)
(n ¼ 272)
8.7  17.4 (11.1 to 6.2)
(n ¼ 197)
Diabetes mellitus
type 2
154.6  18.0
(n ¼ 698)
7.5  17.3 (9.1 to 5.9)
(n ¼ 442)
7.3  17.8 (9.1 to 5.6)
(n ¼ 406)
8.2  17.6 (10.3 to 6.0)
(n ¼ 264)
10.2  17.9 (12.7 to 7.7)
(n ¼ 201)
Isolated systolic
hypertension
152.2  16.8
(n ¼ 707)
6.0  17.3 (7.7 to 4.4)
(n ¼ 435)
5.9  17.6 (7.7 to 4.2)
(n ¼ 389)
9.1  17.9 (11.3 to 6.9)
(n ¼ 266)
8.6  18.7 (11.2 to 6.0)
(n ¼ 199)
Chronic kidney
disease
154.3  19.1
(n ¼ 455)
5.6  19.0 (7.9 to 3.4)
(n ¼ 271)
6.4  18.5 (8.8 to 4.0)
(n ¼ 229)
7.0  21.1 (10.4 to 3.7)
(n ¼ 155)
10.1  20.3 (13.8 to 6.3)
(n ¼ 116)
Atrial fibrillation 153.6  18.0
(n ¼ 232)
9.2  17.9 (12.1 to 6.2)
(n ¼ 143)
10.8  19.1 (14.1 to 7.5)
(n ¼ 132)
11.0  20.6 (15.3 to 6.8)
(n ¼ 93)
10.0  19.1 (14.5 to 5.4)
(n ¼ 70)
Office SBP, mm Hg
Resistant
hypertension
175.4  19.8
(n ¼ 1,822)
19.8  24.3 (21.1 to 18.5)
(n ¼ 1,396)
20.7  25.0 (22.0 to 19.3)
(n ¼ 1,331)
22.2  25.6 (23.8 to 20.7)
(n ¼ 1,043)
23.5  27.2 (25.3 to 21.7)
(n ¼ 837)
Age $65 yrs 165.6  24.7
(n ¼ 1,059)
12.7  26.7 (14.6 to 10.9)
(n ¼ 804)
12.6  27.0 (14.5 to 10.7)
(n ¼ 760)
14.3  27.7 (16.6 to 12.1)
(n ¼ 596)
18.4  28.3 (20.9 to
15.8) (n ¼ 472)
Diabetes mellitus
type 2
165.4  22.6
(n ¼ 978)
13.7  24.5 (15.4 to 11.9)
(n ¼ 766)
13.4  25.9 (15.2 to 11.5)
(n ¼ 739)
15.5  26.9 (17.7 to 13.2)
(n ¼ 549)
16.4  26.8 (18.8 to 13.9)
(n ¼ 465)
Isolated systolic
hypertension
163.8  16.8
(n ¼ 995)
12.3  23.6 (13.3 to 10.6)
(n ¼ 779)
12.7  23.8 (14.4 to 10.9)
(n ¼ 731)
14.1  23.6 (16.0 to 12.1)
(n ¼ 553)
15.9  23.7 (18.0 to 13.7)
(n ¼ 477)
Chronic kidney
disease
163.6  25.7
(n ¼ 609)
12.1  27.3 (14.6 to 9.6)
(n ¼ 463)
9.8  26.8 (12.3 to 7.2)
(n ¼ 427)
10.9  27.9 (14.0 to 7.9)
(n ¼ 327)
11.6  29.6 (15.2 to 7.9)
(n ¼ 254)
Atrial fibrillation 162.6  23.6
(n ¼ 317)
13.7  25.4 (16.9 to 10.5)
(n ¼ 243)
15.2  26.2 (18.6 to 11.9)
(n ¼ 235)
13.9  26.7 (17.8 to 10.1)
(n ¼ 188)
17.6  27.4 (22.1 to 13.1)
(n ¼ 144)
Values are mean  SD (95% confidence interval).
SBP ¼ systolic blood pressure.
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2882and $20%. Changes in BP over time and adverse
event rates were compared for the following sub-
groups: AF versus no AF, age $65 years versus
age <65 years, DM versus no DM, and ISH
versus non-ISH patients. A 2-tailed p value <0.05
was considered statistically significant, unless
otherwise indicated. Analyses were performed
using SAS version 9.4 (SAS Institute, Cary,
North Carolina).
RESULTS
As of March 2019, there were 2,652 patients enrolled
at 196 centers in 45 countries, with 2,466 patients
reaching 3-year follow-up at the time of this report. A
total of 99.8% had a history of hypertension. Median
follow-up was close to 3 years. Reductions in office
and 24-h SBP for the entire population were sustained
from 6 to 36 months post-procedure (Table 1). Base-
line ASCVD risk scores were calculated for 1,485 pa-
tients (56% of total) primarily due to missing
cholesterol measurements. The median ASCVD risk
score was 19.8% (Q1, Q3: 9%, 37%). BP reduction in
patients with measurements at 6, 12, 24, and36 months showed similar reductions in office and
24-h SBP for differing baseline ASCVD risk scores
(Table 2).
BP reduction in several high-risk cohorts was
consistent and sustained across the groups from
6 months to 3 years post-RDN (Table 3). In addition,
SBP reduction was compared between subgroups and
similar decreases in office (Figure 1) and 24-h SBP
(Figure 2) were observed.
Patients with highest baseline ASCVD risk scores
($20%) had higher 3-year rates of death (8.4%), CV
death (4.5%), and hospitalization for new-onset heart
failure (5.3%) or AF (6.3%) compared with patients
with lower risk scores (Table 4). Adverse events at 3
years were similar between subgroups (Table 5),
although several exceptions to this are noted. For
patients with versus without DM, there was a higher
rate of myocardial infarction (4.0% vs. 1.6%;
p ¼ 0.002), end-stage renal disease (2.8% vs. 1.0%;
p ¼ 0.005), and elevated creatinine levels (2.4% vs.
0.8%; p ¼ 0.007). Death and CV death rates at 3 years
were higher for patients age $65 years and patients
with DM. Patients with versus without AF had higher
rates of death (9.2% vs. 3.1%; p < 0.001). ISH patients
FIGURE 1 Changes in Office SBP at 6, 12, 24, and 36 Months
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Patients with (A) age <65 years vs. $65 years; (B) ISH vs. non-ISH; (C) AF vs. no AF; (D) DM vs. no DM. Between-group comparisons and blood pressure (BP) changes
are analysis of covariance–adjusted for baseline BP and shown for all patients eligible for 6-month follow-up. All p values are analysis of covariance–adjusted for
baseline BP. Statistical significance is defined as p < 0.0125 by Bonferroni adjustment. Within each group, p < 0.001 at all time points vs. baseline. AF ¼ atrial
fibrillation; DM ¼ diabetes mellitus; ISH ¼ isolated systolic hypertension; OSBP ¼ office systolic blood pressure.
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2883had a higher rate of CV death than non-ISH patients
(4.0% vs. 2.2%; p ¼ 0.04).
DISCUSSION
Identification of patient cohorts that may derive
specific benefit from RDN is important in the
context of wider implementation of this therapy inclinical practice and requires balancing of the po-
tential procedural risks against the expected bene-
fits from BP lowering and other RDN-induced
effects. Patients at high CV risk represent a poten-
tial target cohort. This post hoc analysis from the
largest real-world registry of RDN demonstrated
clinically and statistically significant reductions in
office and 24-h BP in the entire cohort that were
FIGURE 2 Changes in Mean 24-h SBP at 6, 12, 24, and 36 Months
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other abbreviations as in Figure 1.
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2884maintained out to at least 3 years following the
procedure with low adverse event rates (Central
Illustration). The number of prescribed antihyper-
tensive medications for all patients differed slightly
from baseline to 3 years (4.56  1.36; n ¼ 2,621 vs.
4.39  1.45; n ¼ 2,449; p < 0.001), but changes were
not clinically significant, as opposed to what was
reported in a smaller RDN registry (7). It is unlikelythat changes in medication contributed to the
observed decrease in BP, although adherence mea-
surements were not performed routinely. The
baseline adjusted BP-lowering effects were similar
across subgroups. BP reductions were not depen-
dent on baseline CV risk, although, expectedly,
more adverse clinical events occurred in higher CV-
risk subgroups. Overall, these results indicate a safe
TABLE 4 Adverse Events at 3 Years for Patients With Different Baseline ASCVD Risk Scores
ASCVD Risk Score
<10%
(n ¼ 290)
$10% to <20%
(n ¼ 239)
$20%
(n ¼ 510) p Value
Follow-up, days 1,095
(788, 1,095)
1,095
(787, 1,095)
1,089
(711, 1,095)
Death 1.0 (3/290) 2.1 (5/239) 8.4 (43/510) <0.001
Cardiovascular death 1.0 (3/290) 0.8 (2/239) 4.5 (23/510) 0.002
MI 2.1 (6/290) 2.5 (6/239) 2.2 (11/510) 0.94
Stroke 3.1 (9/290) 3.8 (9/239) 4.7 (24/510) 0.53
New-onset end-stage renal disease 0.7 (2/290) 1.3 (3/239) 2.2 (11/510) 0.29
Serum creatinine elevation >50% 0.7 (2/290) 1.7 (4/239) 2.2 (11/510) 0.31
New renal artery stenosis >70% 0.3 (1/290) 0.0 (0/239) 0.6 (3/510) 0.81
Hospitalization for new-onset heart failure 1.7 (5/290) 2.9 (7/239) 5.3 (27/510) 0.03
Hospitalization for atrial fibrillation 2.1 (6/290) 2.1 (5/239) 6.3 (32/510) 0.003
Hospitalization for hypertensive crisis/ hypertensive emergency 3.4 (10/290) 2.9 (7/239) 2.9 (15/510) 0.91
Values are median (Q1, Q3) or % (n/N).
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2885and durable BP response to RDN in a wide range of
patients with uncontrolled BP by conventional drug
therapy, including those at high CV risk.
The GSR includes a large population of patients
over the age of 65 years (n ¼ 1,059) compared with
the recent sham controlled trials of RDN (1–3). We
observed office and 24-h SBP reductions in patients
age $65 years that were sustained to 3 years.
Interestingly, the BP reductions were similar for
patients above compared with below age 65 years.
These results are consistent with a previous report
(7) also showing significant BP reductions at
6 months in patients of age $75 years.TABLE 5 Rate of Adverse Events at 36 Months for Entire Population
All Patients
(N ¼ 1,749)
Age $65 yrs
(n ¼ 741)
Age <65 yrs
(n ¼ 1,008) p Value (n
Death 5.7
(99/1,749)
9.2
(68/741)
3.1
(31/1,008)
<0.001
(
Cardiovascular
death
2.9
(51/1,749)
4.6
(34/741)
1.7
(17/1,008)
<0.001
(
Myocardial
infarction
2.5
(44/1,749)
2.4
(18/741)
2.6
(26/1,008)
0.84
(
Stroke 4.5
(79/1,749)
5.0
(37/741)
4.2
(42/1,008)
0.41
(
End-stage renal
disease
1.8
(32/1,749)
2.2
(16/741)
1.6
(16/1,008)
0.38
(
Creatinine
elevation
>50%
1.4
(25/1,749)
1.5
(11/741)
1.4
(14/1,008)
0.87
(
New renal
artery
stenosis
>70%
0.3
(6/1,749)
0.3
(2/741)
0.4
(4/1,008)
1.00
(
Hospitalizations
for HTN
crisis
3.1
(55/1,749)
3.4
(25/741)
3.0
(30/1,008)
0.64
(
Values are % (n/N).
AF ¼ atrial fibrillation; DM ¼ diabetes mellitus; HTN ¼ hypertension; ISH ¼ isolated sA post hoc analysis from previous trials and a
single-center study both reported less BP reduction
for ISH patients after RDN compared with patients
with combined systolic-diastolic hypertension (8,9).
However, decreases in SBP from our analysis were not
different between patients with ISH compared with
those without. The present analysis encompasses
more patients with longer follow-up and also adjusts
for differences in baseline SBP. This is supported by a
recent subanalysis of the prospective, randomized,
uncontrolled RADIOSOUND (Randomized Compari-
son of Ultrasound Versus Radiofrequency Denerva-
tion in Patients With Therapy Resistantand Individual Subgroups
ISH
¼ 676)
Non-ISH
(n ¼ 1,028) p Value
AF
(n ¼ 236)
No AF
(n ¼ 1,503)
p
Value
DM
(n ¼ 675)
Non-DM
(n ¼ 1,016)
p
Value
6.5
44/676)
5.0
(51/1,028)
0.17 8.5
(20/236)
5.3
(79/1,503)
0.047 7.1
(48/675)
4.5
(46/1,016)
0.02
4.0
27/676)
2.2
(23/1,028)
0.04 4.7
(11/236)
2.7
(40/1,503)
0.09 4.0
(27/675)
2.0
(20/1,016)
0.01
2.8
19/676)
2.2
(23/1,028)
0.46 2.5
(6/236)
2.4
(36/1,503)
0.89 4.0
(27/675)
1.6
(16/1,016)
0.002
4.7
32/676)
4.4
(45/1,028)
0.73 3.8
(9/236)
4.6
(69/1,503)
0.59 4.0
(27/675)
4.6
(47/1,016)
0.54
2.7
18/676)
1.4
(14/1,028)
0.053 1.3
(3/236)
1.9
(29/1,503)
0.61 2.8
(19/675)
1.0
(10/1,016)
0.005
1.5
10/676)
1.5
(15/1,028)
0.97 0.8
(2/236)
1.5
(23/1,503)
0.56 2.4
(16/675)
0.8
(8/1,016)
0.007
0.3
2/676)
0.3
(3/1,028)
1.00 0.8
(2/236)
0.3
(4/1,503)
0.19 0.3
(2/675)
0.3
(3/1,016)
1.00
2.4
16/676)
3.7
(38/1,028)
0.13 3.0
(7/236)
3.1
(47/1,503)
0.89 3.4
(23/675)
2.8
(28/1,016)
0.44
ystolic hypertension.
CENTRAL ILLUSTRATION Effects of Renal Denervation in Patients With and Without Various Comorbidities
Mahfoud, F. et al. J Am Coll Cardiol. 2020;75(23):2879–88.
CV ¼ cardiovascular.
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2886Hypertension) trial, which showed no difference in
the adjusted drop in 24-h mean SBP in ISH patients
compared with combined hypertension patients (10).
Further randomized controlled trials in patients with
ISH are warranted to clarify the response to RDN in
this high-risk cohort (8).
Increased sympathetic activity is implicated in both
the initiation and maintenance of atrial tachyar-
rhythmias including AF (11). Most previous trials of
RDN, including SPYRAL HTN-OFF MED and SPYRALHTN-ONMED, included relatively small proportions of
patients with AF history (1,3). In the present analysis,
office and 24-h SBP reductions were similar for pa-
tients with versus without AF. Interestingly, recent
reports including prospective randomized trials in
patients with hypertensive heart disease and in pa-
tients with both AF and uncontrolled hypertension
have shown significant reductions in AF burden
following RDN alone (12) and in combination with
pulmonary vein isolation (PVI) (13). Ongoing
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2887prospective randomized trials are further evaluating
the role of RDN in patients indicated for PVIwith a history
of hypertension (NCT02064764 and NCT02115100).
Patients with higher baseline CV risk, regardless of
comorbidity, may derive particular benefit from BP
reduction. Indeed, the current American Heart Asso-
ciation/American College of Cardiology guidelines for
BP control stratify recommended drug therapy for
patients with stage 1 hypertension based on ASCVD
risk >10% (14). The GSR subgroups stratified by
baseline CV risk score were not associated with a
different BP response, including patients with risk
above or below 10% (Table 2). A previous meta-
analysis also found that the estimated number of
avoidable CV events increased with higher baseline
CV risk and more pronounced BP reduction (15).
Therefore, patients with high CV risk might particu-
larly benefit from RDN therapy, which may also
extend to cost effectiveness.
Renal nerves have been shown to anatomically
recover following ablation in some anatomical
models (16). However, functional recovery of nerves
following radiofrequency (RF) RDN in animal and
humans is uncertain (4). A recent preclinical study in
sheep with hypertensive chronic kidney disease
showed regrowth of renal nerves and return of
function at 30 months following RF-RDN, but levels
were only partially restored to levels of intact, sug-
gesting that RDN lowers BP in the long-term and is
renoprotective and cardioprotective as a result of
lesser nerve regrowth in chronic kidney disease (4).
Therefore, clinical evidence of the long-term dura-
bility of RDN is vital to determine its potential
impact on hypertension control rates (17). Long-term
renal function and durability of BP reduction
following RDN was previously reported for GSR, the
SYMPLICITY HTN-1 and HTN-2 trials, and a smaller
registry from Sweden (18–20). To date, GSR is the
largest RDN registry with 3-year results corrobo-
rating prior evidence of the durability of the RDN
procedure.
Long-term safety following the RDN procedure re-
mains of utmost importance formultiple stakeholders,
including patients, clinicians, regulators, and payers.
Short-term reports of adverse events following RDN
with both RF and ultrasound-based devices have been
encouraging (1–3). Likewise, a previous report from
GSR that focused on patients treated with the first-
generation single-electrode RF device showed favor-
able short- and long-term safety with adverse events
proportionate to the basal risk of the population (20).
Current results report a low 3-year rate of 0.3% for new
renal artery stenosis >70%, and previous work sug-
gests the 3-year rate of natural renal artery diseaseprogression is up to 18% in renal arteries categorized as
normal at baseline (21). Moreover, the present results
show that clinical event rates following RDN are
expectedly related to the baseline comorbidity profile.
Results from a meta-analysis suggest that a 10-mm Hg
reduction in office SBP leads to a 13% reduction in all-
cause mortality (22), and mean office SBP reduction at
3 years in GSR was 16.5 mm Hg. Therefore, because the
risks associated with RDN appear to be reasonably low,
the potential to reduce clinical events by RDN treat-
ment to lower BP independent of BP drug therapy re-
mains high.
STUDY LIMITATIONS. The current report includes a
post hoc analysis from a large, prospective, single-
arm, open-label, real-world registry. As often
observed in registries, not all patients were available
for 3-year follow-up, and no control group was
available for comparison. However, the overall large
number of patients available and the extended
duration of follow-up clearly demonstrated a persis-
tent BP reduction over 3 years. Baseline BP has been
reported to be a predictor of BP drop, and several of
the comparison subgroups had different baseline SBP
(23). However, these differences were appropriately
adjusted using ANCOVA (24), and the benefit in BP
reduction was consistent. CV risk scores could not be
recalculated at follow-up, because serum cholesterol
measurement was not mandatory. However, because
SBP is a key determinant of risk, one might assume
that calculated risk improved in this group.
CONCLUSIONS
BP reduction after RDN was similar in patients with
and without baseline conditions associated with
increased sympathetic activity and irrespective of
ASCVD risk. The reduction in BP was sustained to 3
years, demonstrating the durability of BP reduction
by RDN across various subgroups, particularly in pa-
tients with high CV risk. Rates of new-onset end-stage
renal disease and elevation in serum creatinine levels
were very low in patients at high and low CV risk.
Clinical events increased with increasing ASCVD risk
score, and elevated rates were also seen in patients
with AF and diabetes, identifying these subgroups
who might derive even greater clinical benefit from
improved BP control using RDN.
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PERSPECTIVES
COMPETENCY IN PATIENTCAREANDPROCEDURAL
SKILLS: In a large global registry, renal denervation
resulted in similar reductions of blood pressure in hy-
pertensive patients across a wide range of cardiovascular
risk.
TRANSLATIONAL OUTLOOK: Future studies should
assess the efficacy of renal denervation to prevent major
adverse cardiovascular events in patients with isolated
systolic and other specified forms of hypertension.
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